LHLaura Herrero-Vidal

Laura Herrero-Vidal

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Laura Herrero-Vidal has a total of 9 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Investigación en actividad física en cáncer de próstata: una revisión bibliométrica basada en Scopus (1991-2025)

    by Daniel González-Devesa, Ruben Toledo-Pozuelo, Alejandro Soler-López, Carlos D. Gómez-Carmona, Alberto González-Costea, Laura Herrero-Vidal, Enrique Cao-Avellaneda, Daniel López-Plaza

    Prostate cancer is among the most prevalent malignancies worldwide, and physical exercise has emerged as a key non-pharmacological intervention to mitigate treatment-related side effects. Objectives: This study aimed to analyze the evolution, productivity, and research trends in the field of exercise and prostate cancer between 1991 and 2025. Methods: A bibliometric analysis was conducted using the Scopus database. Performance indicators were evaluated by country, institution, and author. Additionally, keyword co-occurrence analysis and thematic mapping were performed using Bibliometrix to characterize the intellectual structure and evolution of the field. A total of 263 documents published across 132 journals were included, revealing steady growth with a compound annual growth rate of 8.69%. Notably, over 30% of total output was published in the last five years, with the United States, Canada, and Australia leading scientific production. Thematic analysis revealed a maturation of the field, shifting from early concepts of survival and risk toward current focuses on quality of life, resistance training, and managing the effects of androgen deprivation therapy (ADT). Research on exercise and prostate cancer is experiencing robust expansion. These findings support the integration of supervised exercise programs into standard onco-logical care and highlight the need for future multicenter randomized trials to determine optimal exercise prescriptions, moving the field toward a precision-medicine paradigm.

  • Open Access

    lactate threshold-based incremental treadmill training and assessment protocol (LACTOC) for managing treatment-induced cardiotoxicity in oncology patients

    by Alejandro Soler-López, Enrique Cao-Avellaneda, Laura Herrero-Vidal, Daniel González-Devesa, Daniel López-Plaza, Rubén Toledo-Pozuelo, Alberto González-Costea, Carlos D. Gómez-Carmona

    Cardiotoxicity represents a clinically significant complication in oncology patients, manifesting as cardiac dysfunction that impairs functional capacity and quality of life. Physical exercise has emerged as a promising intervention to mitigate treatment-related adverse effects; however, optimal exercise prescription for patients with cardiotoxicity remains poorly defined, as most existing protocols rely on heart rate percentages or peak oxygen consumption—methods imprecise in cardiovascularly compromised populations. This protocol describes the LACTOC program, a 4-week supervised treadmill exercise intervention comprising 12 sessions (three per week, 48-hour recovery intervals) in oncology patients with treatment-induced cardiotoxicity. Each session includes a warm-up (5 min at 3 km/h), a progressive incremental test with 3-minute stages and 1 km/h increments from 4 km/h until reaching 4 mmol/L blood lactate or 85% of theoretical maximal heart rate, and active recovery (5 min at 3 km/h). Comprehensive cardiovascular, metabolic, perceptual, and heart rate variability monitoring is integrated throughout. The protocol is expected to enable individualized exercise prescription based on objective metabolic thresholds, with session-by-session load adjustment guided by daily HRV assessment representing a methodological advance over conventional fixed-prescription approaches. This proposal is positioned as a promising framework for cardio-oncological rehabilitation, providing objective tools to guide safe and effective exercise prescription in patients with treatment-induced cardiotoxicity.